健康受试者空腹和餐后状态下单剂量口服贝前列素钠片(40μg)的随机、开放、两制剂、两序列、四周期、完全重复交叉生物等效性试验
[Translation] A randomized, open-label, two-formulation, two-sequence, four-cycle, fully replicated crossover bioequivalence trial of single-dose oral beraprost sodium tablets (40 μg) in healthy subjects under fasting and postprandial conditions
主要目的:比较空腹和餐后单次给药条件下,北京康晟百春生物科技有限公司持证的贝前列素钠片(规格:40μg,受试制剂)与武田テバファーマ株式会社(Teva Pharma Japan Inc)持证的贝前列素钠片(规格:40μg,参比制剂)在健康受试者中吸收程度和速度的差异。通过主要药代动力学参数,评价两者是否生物等效。
次要目的:通过观察健康受试者单次口服受试制剂和参比制剂后的安全性指标,评价贝前列素钠片的安全性。
[Translation] Main purpose: To compare the licensed beraprost sodium tablets (specification: 40 μg, test preparation) of Beijing Kangsheng Baichun Biotechnology Co., Ltd. and Takeda Pharma Japan Co., Ltd. under fasting and single-dose administration conditions after meals. Inc)'s certified beraprost sodium tablets (specification: 40μg, reference preparation) in healthy subjects. Through the main pharmacokinetic parameters, evaluate whether the two are bioequivalent.
Secondary purpose: To evaluate the safety of beraprost sodium tablets by observing the safety indicators of healthy subjects after a single oral administration of the test preparation and reference preparation.
[Translation] Study on human bioequivalence of faropenem sodium granules in children
主要目的:采用单剂量、随机、开放、双周期交叉、空腹及餐后口服给药设计,比较北京康晟百春生物科技有限公司持证的小儿法罗培南钠颗粒(规格:0.05 g,按C12H15NO5S计)与Maruho Co.,Ltd.(玛路弘株式会社)持证的小儿法罗培南钠颗粒(规格:0.05 g,按C12H15NO5S计)在中国健康人群中吸收程度和吸收速度的差异,评价生物等效性。
次要目的:评价小儿法罗培南钠颗粒(规格:0.05 g,按C12H15NO5S计)受试制剂和参比制剂在健康受试者体内的安全性。
[Translation] Main purpose: To compare Beijing Kangsheng Baichun Biotechnology Co., Ltd.'s licensed pediatric faropenem sodium granules (specification: 0.05 g, according to C12H15NO5S) using a single-dose, random, open, two-cycle crossover, fasting and postprandial oral administration design. (calculated) and Maruho Co., Ltd. (Maruho Co., Ltd.) certified pediatric faropenem sodium granules (specification: 0.05 g, calculated as C12H15NO5S) in Chinese healthy people, the difference in the degree and rate of absorption, evaluation biology, etc. effectiveness.
Secondary purpose: To evaluate the safety of the test preparation and reference preparation of pediatric faropenem sodium granules (specification: 0.05 g, calculated as C12H15NO5S) in healthy subjects.
100 Clinical Results associated with Beijing Kangsheng Baichun Biotechnology Co., Ltd.
0 Patents (Medical) associated with Beijing Kangsheng Baichun Biotechnology Co., Ltd.
100 Deals associated with Beijing Kangsheng Baichun Biotechnology Co., Ltd.
100 Translational Medicine associated with Beijing Kangsheng Baichun Biotechnology Co., Ltd.